A Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease
Status:
Terminated
Trial end date:
2018-10-03
Target enrollment:
Participant gender:
Summary
The purpose of this study was to evaluate the safety and tolerability, and the
pharmacokinetic and biologic activity of INCB059872 in participants with sickle cell disease.